BioMarin Announces Positive Phase 3 Results for VOXZOGO® in Hypochondroplasia, Published in NEJM Evidence

BioMarin has reported new positive data from its Phase 3 CANOPY-HCH-3 study of VOXZOGO® (vosoritide) for children with hypochondroplasia. The findings, published in NEJM Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting, showed statistically significant improvements in annualized growth velocity, standing height, height Z-score, and arm span after 52 weeks of treatment. Patients are advised to eat a meal and drink fluids within an hour before receiving VOXZOGO to reduce the risk of blood pressure decrease.

Context

Hypochondroplasia is a form of skeletal dysplasia that leads to shorter stature and other growth-related challenges. Current treatment options for this condition are limited, making new therapies like VOXZOGO® critical. BioMarin's previous work in rare genetic disorders positions it as a key player in this field.

Why it matters

The positive results from BioMarin's Phase 3 study of VOXZOGO® represent a significant advancement in treatment options for children with hypochondroplasia, a genetic condition affecting growth. Improved growth metrics can enhance the quality of life for affected children and their families. This development may also influence future research and funding in pediatric growth disorders.

Implications

If approved, VOXZOGO® could become a standard treatment for children with hypochondroplasia, potentially changing clinical practices. This may lead to increased demand for monitoring and support services for affected families. Additionally, successful outcomes could encourage investment in similar therapies for other growth disorders.

What to watch

Following these promising results, regulatory discussions may accelerate as BioMarin seeks approval for VOXZOGO® in treating hypochondroplasia. The upcoming European Society for Paediatric Endocrinology Annual Meeting will likely feature further discussions on the implications of these findings. Stakeholders will be monitoring responses from healthcare providers and patient advocacy groups.